Related Experiment Video
Updated: May 23, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Tunicamycin inhibits diabetes
Namir Shaabani1, Nadine Honke, Philipp A Lang
1Department of Gastroenterology, Hepatology and Infectious diseases, University of Düsseldorf, Germany.
Background:
Autoimmune diseases are characterized by a breakdown of immunologic tolerance, and this breakdown can lead to life-threatening or lifelong disorders. Moreover; drugs that are used to treat these diseases are few in number and are associated with many serious adverse effects.
Methods:
We used the rat insulin promoter-glycoprotein mouse model to analyze the role of tunicamycin in the process of autoimmune diabetes; the P14 mouse model to analyze the effect of tunicamycin on CD8(+) T cells; chop knockout mice to analyze the role of tunicamycin on an endoplasmic reticulum stress model; and fluorescence-activated cell sorting, quantitative real-time polymerase chain reaction, and histologic methods.
Results:
We found that a single dose of tunicamycin reduced the activation and pancreatic infiltration of CD8(+) T cells. This activity delayed the incidence of virus-induced diabetes and improved survival rates.
Conclusion:
Tunicamycin may offer therapeutic opportunities for T cell-mediated autoimmune diseases such as diabetes.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Biguanides and Glitazones
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Type II Diabetes II: Pathophysiology
Diabetic Nephropathy
